Michael S Schechter
Affiliation: Emory University
- Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosisMichael S Schechter
Division of Pulmonary, Allergy Immunology, Cystic Fibrosis and Sleep, Emory University School of Medicine, Atlanta, GA 30322, USA
J Pediatr 155:634-9.e1-4. 2009....
- Airway clearance applications in infants and childrenMichael S Schechter
Department of Pediatrics, Emory University School of Medicine, Emory Children s Center, 2015 Uppergate Drive, Suite 326, Atlanta, GA 30322 0001
Respir Care 52:1382-90; discussion 1390-1. 2007..All in all, however, given that these conclusions are based on very little data, future well-performed clinical trials might change the weight of evidence to contradict these current conclusions...
- Nongenetic influences on cystic fibrosis outcomesMichael S Schechter
Division of Pulmonary, Allergy Immunology, Cystic Fibrosis and Sleep, Department of Pediatrics, Emory University School of Medicine, 1547 Clifton Road, Atlanta, GA 30322, USA
Curr Opin Pulm Med 17:448-54. 2011....
- Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosisMichael S Schechter
Emory University School of Medicine and Children s Healthcare of Atlanta, Atlanta, GA, USA
J Pediatr 159:819-824.e1. 2011..To determine whether socioeconomic status (SES) influences the likelihood of antibiotic treatment of pulmonary exacerbations in patients with cystic fibrosis (CF)...
- Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung functionClement L Ren
Department of Pediatrics, University of Rochester, Rochester, New York 14642, USA
Pediatr Pulmonol 42:513-8. 2007..Similar results were seen in patients >or=18 years old. The results of our study highlight the growing clinical impact of MRSA infections in CF patients...
- Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosisClement L Ren
Department of Pediatrics, University of Rochester, Rochester, NY, USA
J Pediatr 153:746-51. 2008....
- Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung functionRaj Padman
Department of Pediatrics, Alfred I duPont Hospital for Children, Nemours Children s Clinic, Wilmington, DE 19899, USA
Pediatrics 119:e531-7. 2007..The aim of this study was to assess whether patterns of care for infants at cystic fibrosis sites with superior average lung function in 6- to 12-year-old children showed any differences from those at the lowest outcome sites...
- Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptomsWarren E Regelmann
Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
Pediatr Pulmonol 48:649-57. 2013....
- Genetic and non-genetic determinants of outcomes in cystic fibrosisLinda L Wolfenden
Emory Cystic Fibrosis Center, Emory University, Atlanta, Georgia, USA
Paediatr Respir Rev 10:32-6. 2009..Many factors contribute to improvements in disease severity and outcome. This paper reviews the current evidence of three groups of important factors: genetic, environmental and healthcare related...
- Healthcare expenditures for privately insured people with cystic fibrosisLijing Ouyang
National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Pediatr Pulmonol 44:989-96. 2009..People with CF will incur high medical expenditures throughout their lifespan. These findings will assist in the development of economic evaluations of future CF screening and management initiatives...
- Benchmarking to improve the quality of cystic fibrosis careMichael S Schechter
Emory University School of Medicine, Children s Healthcare of Atlanta, Atlanta, Georgia 30322, USA
Curr Opin Pulm Med 18:596-601. 2012..This review summarizes reports of how benchmarking has been operationalized in attempts to improve CF care...
- Non-genetic influences on CF lung disease: the role of sociodemographic characteristics, environmental exposures and healthcare interventionsMichael S Schechter
Department of Pediatrics, Rhode Island Hospital, 593 Eddy Street, Suite POB 440, Providence, RI 02903, USA
Pediatr Pulmonol Suppl 26:82-5. 2004
- Testing the feasibility of a National Spina Bifida Patient RegistryJudy K Thibadeau
Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, Atlanta, GA 30333, USA
Birth Defects Res A Clin Mol Teratol 97:36-41. 2013....
- Improving the quality of care for patients with cystic fibrosisMichael S Schechter
Department of Pediatrics, Division of Pulmonary, Allergy Immunology, Cystic Fibrosis and Sleep, Emory University School of Medicine, Children s Healthcare of Atlanta, Atlanta, Georgia 30322, USA
Curr Opin Pediatr 22:296-301. 2010..This article describes the factors that have contributed to the recent acceleration in this improvement and the important role of the Cystic Fibrosis Foundation...
- Improving subspecialty healthcare: lessons from cystic fibrosisMichael S Schechter
Department of Pediatrics, Brown Medical School, Rhode Island Hospital Hasbro Children s Hospital, Providence, Rhode Island 02903, USA
J Pediatr 147:295-301. 2005
- Sweat-testing in preterm and full-term infants less than 6 weeks of ageWarren Eng
Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7145, USA
Pediatr Pulmonol 40:64-7. 2005..In conclusion, sweat collection can be reliably performed in infants > or = 36 weeks postmenstrual age, > 2,000 g, and > 3 days postnatal age. Maturational factors have a mild impact on sweat chloride concentration...
- Effect of macrolides on in vivo ion transport across cystic fibrosis nasal epitheliumPierre M Barker
Department of Pediatrics, University of North Carolina at Chapel Hill, 200 Mason Farm Road, Chapel Hill, NC 27599 7220, USA
Am J Respir Crit Care Med 171:868-71. 2005..We conclude that the apparent beneficial effects of macrolides on pulmonary outcome in CF are not mediated by their modulation of ion transport...
- Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutationJ P Clancy
Department of Pediatrics, Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
Thorax 67:12-8. 2012..VX-809, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, has been shown to increase the cell surface density of functional F508del-CFTR in vitro...
- Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapyIngrid M Hoffmann
Department of Pediatrics, Wake Forest University School of Medicine Baptist Medical Center, Winston Salem, North Carolina 27157 1081, USA
Pediatr Pulmonol 34:375-7. 2002..Measurable tobramycin levels due to inhalational therapy with conventional dosing in the reported patient indicate that the drug can be systemically absorbed, and renal tubular toxicity may occur...
- Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosisKenneth N Olivier
The Cystic Fibrosis Pulmonary Research and Treatment Center, The Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
Am J Respir Crit Care Med 167:828-34. 2003..Older age was the most significant predictor for isolation of NTM. The clinical significance of NTM in CF is incompletely defined, but patients with these organisms should be monitored with repeat cultures...